MediWound Ltd. (MDWD) |
|
1.66 0.01 (0.61%)
|
11-25 12:59 |
|
Open: |
1.65 |
Pre. Close: |
1.65 |
|
High:
|
1.69 |
Low:
|
1.62 |
|
Volume:
|
81,483 |
Market Cap:
|
68(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 1:58:42 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.97  One year: 2.3 |
| Support: |
Support1: 1.41 Support2: 1.24 |
| Resistance: |
Resistance1: 1.69 Resistance2: 1.97 |
| Pivot: |
1.47 |
| Moving Average: |
MA(5): 1.57 MA(20): 1.45
MA(100): 1.64  MA(250): 1.93 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 85.5 %D(3): 73.4 |
| RSI: |
RSI(14): 62.1 |
| 52-week: |
High: 3.38 Low: 1.21 |
| Average Vol(K): |
3-Month: 130 (K) 10-Days: 148 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MDWD ] has closed below upper band by 8.9%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.67 - 1.68 |
1.68 - 1.68 |
|
Low:
|
1.53 - 1.54 |
1.54 - 1.55 |
|
Close:
|
1.64 - 1.65 |
1.65 - 1.66 |
|
Company Description |
|
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. |
Headline News |
Tue, 15 Nov 2022
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq
Tue, 15 Nov 2022
MediWound Misses Q3 EPS by 28c By Investing.com - Investing.com
Tue, 15 Nov 2022
MediWound: Q3 Earnings Snapshot - The Advocate
Tue, 15 Nov 2022
Mediwound Earnings Miss, Revenue Beats In Q3 By Investing.com - Investing.com
Tue, 15 Nov 2022
MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript - Seeking Alpha
Thu, 10 Nov 2022
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
41 (M) |
|
% Held by Insiders
|
2.54e+007 (%) |
|
% Held by Institutions
|
32.2 (%) |
|
Shares Short
|
71 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.295e+007 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.76 |
|
EPS Est Next Year
|
-0.65 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
-80.1 |
|
Operating Margin (%)
|
-67.2 |
|
Return on Assets (ttm)
|
-33.1 |
|
Return on Equity (ttm)
|
-3 |
|
Qtrly Rev. Growth
|
2.036e+007 |
|
Gross Profit (p.s.)
|
-8.56 |
|
Sales Per Share
|
869.87 |
|
EBITDA (p.s.)
|
8.43269e+006 |
|
Qtrly Earnings Growth
|
-0.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
43.15 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
47100 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
